Randomized Trial of Intracoronary Adenosine As Adjunctive Therapy for Prevention of the No-Reflow Phenomenon

Randomized Trial of Intracoronary Adenosine As Adjunctive Therapy for Prevention of the No-Reflow Phenomenon Publisher Pubmed

Naghshtabrizi N¹ ; Sajedi M² ; Naghshtabrizi B³ ; Mozayanimonfared A³ ; Ali Seif Rabiei M⁴ ; Kanonisabet A⁵

Show Affiliations

1. Department of Cardiology, Tehran University of Medical Science, Tehran, Iran
2. School of Medicine, Hamadan University of Medical Sciences
3. Department of Cardiology, Hamadan University of Medical Science
4. Hamadan University of Medical Science, Hamadan, Iran
5. Department of Cardiology, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Source: Coronary Artery Disease Published:2020

Abstract

No-reflow phenomenon as a serious complication following percutaneous coronary intervention, deteriorates clinical outcomes. Intracoronary (IC) Adenosine, seems to be a way to deal with it. One hundred four consecutive patients with ST-segment elevation myocardial infarction were randomized into two groups. Each group consisted of 52 patients who managed with two bolus doses of IC Adenosine (Adenosine group) or two bolus doses of IC normal saline (placebo group) administered before and after stenting. Thrombolysis in myocardial infarction (TIMI) grade flow, ST-segment resolution (STR) and post-procedural clinical outcomes were used as endpoints. IC adenosine led to lower rates of no-reflow based on TIMI grade flow scaling (15.4% vs. 44.3%; P-value: 0.02). STR classified as complete, partial and no resolution was similar between two groups (P-value: 0.748). Also, post-interventional clinical outcomes, including arrhythmia, left ventricular ejection fraction, hospitalization time, and 30 days mortality were similar between Adenosine and placebo groups. © 2020 Lippincott Williams and Wilkins. All rights reserved.

2. Pharmacologic Prevention of Myocardial Ischemia-Reperfusion Injury in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention, Journal of Cardiovascular Pharmacology (2021)

3. The No-Reflow Phenomenon: Is It Predictable by Demographic Factors and Routine Laboratory Data?, Acta Biomedica (2021)

Experts (# of related papers)

View all Related Experts

Azita Hajhossein Talasaz (2)

Hamid Reza Poorhosseini (1)

Style	Citing Format
MLA	Naghshtabrizi N, et al.. "Randomized Trial of Intracoronary Adenosine As Adjunctive Therapy for Prevention of the No-Reflow Phenomenon." Coronary Artery Disease, vol. 31, no. 6, 2020, pp. 527-529.
APA	Naghshtabrizi N, Sajedi M, Naghshtabrizi B, Mozayanimonfared A, Ali Seif Rabiei M, Kanonisabet A (2020). Randomized Trial of Intracoronary Adenosine As Adjunctive Therapy for Prevention of the No-Reflow Phenomenon. Coronary Artery Disease, 31(6), 527-529.
Chicago	Naghshtabrizi N, Sajedi M, Naghshtabrizi B, Mozayanimonfared A, Ali Seif Rabiei M, Kanonisabet A. "Randomized Trial of Intracoronary Adenosine As Adjunctive Therapy for Prevention of the No-Reflow Phenomenon." Coronary Artery Disease 31, no. 6 (2020): 527-529.
Harvard	Naghshtabrizi N et al. (2020) 'Randomized Trial of Intracoronary Adenosine As Adjunctive Therapy for Prevention of the No-Reflow Phenomenon', Coronary Artery Disease, 31(6), pp. 527-529.
Vancouver	Naghshtabrizi N, Sajedi M, Naghshtabrizi B, Mozayanimonfared A, Ali Seif Rabiei M, Kanonisabet A. Randomized Trial of Intracoronary Adenosine As Adjunctive Therapy for Prevention of the No-Reflow Phenomenon. Coronary Artery Disease. 2020;31(6):527-529.
BibTex	@article{ author = {Naghshtabrizi N and Sajedi M and Naghshtabrizi B and Mozayanimonfared A and Ali Seif Rabiei M and Kanonisabet A}, title = {Randomized Trial of Intracoronary Adenosine As Adjunctive Therapy for Prevention of the No-Reflow Phenomenon}, journal = {Coronary Artery Disease}, volume = {31}, number = {6}, pages = {527-529}, year = {2020} }
RIS	TY - JOUR AU - Naghshtabrizi N AU - Sajedi M AU - Naghshtabrizi B AU - Mozayanimonfared A AU - Ali Seif Rabiei M AU - Kanonisabet A TI - Randomized Trial of Intracoronary Adenosine As Adjunctive Therapy for Prevention of the No-Reflow Phenomenon JO - Coronary Artery Disease VL - 31 IS - 6 SP - 527 EP - 529 PY - 2020 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract